AGOMELATINE IN THE TREATMENT OF ANXIETY AND DEPRESSIVE DISORDERS IN PATIENTS WITH ISCHEMIC HEART DISEASE
According to the World Health Organization, anxiety and depressive disorders will be the second leading cause of disability by 2020. The review is devoted to the modern concepts of the pathophysiology of depression in patients with ischemic heart disease (IHD) and to the possibilities of antidepre...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Столичная издательская компания
2017-03-01
|
| Series: | Рациональная фармакотерапия в кардиологии |
| Subjects: | |
| Online Access: | https://www.rpcardio.online/jour/article/view/1425 |
| Summary: | According to the World Health Organization, anxiety and depressive disorders will be the second leading cause of disability by 2020. The review is devoted to the modern concepts of the pathophysiology of depression in patients with ischemic heart disease (IHD) and to the possibilities of antidepressant therapy. The paper presents analysis of international and domestic researches devoted to efficiency and safety of agomelatine in patients both with chronic IHD and with unstable angina and acute myocardial infarction. The review also discusses different points of view, indicating the need for further studies to evaluate the short and long term effects of antidepressants in patients with IHD in combination with anxiety and depressive disorders. |
|---|---|
| ISSN: | 1819-6446 2225-3653 |